The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …

In the setting of intensive immunosuppression for the management of rejection in solid organ
transplant (SOT) recipients, or graft-versus-host disease (GVHD) in hematopoietic stem cell …

This report updates and combines earlier versions of guidelines for the prevention and
treatment of opportunistic infections (OIs) in HIV-infected adults (ie, persons aged> 18 years) …

Cytomegalovirus (CMV) remains one of the most common infections after solid organ
transplantation, resulting in significant morbidity, graft loss, and occasional mortality …

Cytomegalovirus (CMV) infection is a significant complication in hematopoietic cell
transplantation (HCT) recipients. Four antiviral drugs are used for preventing or treating …

Letermovir (LMV) is an experimental cytomegalovirus terminase inhibitor undergoing phase
3 clinical trials. Viral mutations have been described at UL56 codons 231 to 369 that confer …

Following a year of valganciclovir prophylaxis, a lung transplant recipient developed
cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by …

Cytomegalovirus (CMV) drug resistance mutation maps are updated with recent information
for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor …

The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the
use of antiviral agents that currently target the viral DNA polymerase and that may cause …

Mutations in the human CMV UL97 kinase gene are a major mechanism of viral resistance
to two anti‐CMV drugs, ganciclovir (GCV) and maribavir (MBV). GCV, the most widely used …